Use of chemotherapy and radiotherapy in patients with pancreatic cancer in Victoria (2002-2003): A retrospective cohort study

Medical Journal of Australia

Volumn 192, Issue 6, 2010, Pages 323-327

  Jefford, Michael ^a,b,c   Thursfield, Vicky ^c   Torn Broers, Yvonne ^c   Leong, Trevor ^a   Guerrieri, Mario ^d   Speer, Tony ^e  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CANCER EPIDEMIOLOGY CENTRE   (Australia)

^d Radiation Oncology Victoria   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN;

ADVANCED CANCER; AGED; ARTICLE; AUSTRALIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SURGERY; COHORT ANALYSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PANCREAS CANCER; PATIENT REFERRAL; POPULATION BASED CASE CONTROL STUDY; POSTOPERATIVE PERIOD; QUESTIONNAIRE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 77952410217     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03531.x     Document Type: Article

References (22)

1. Thursfield V, Farrugia H, Giles G. Cancer in Victoria 2006. Canstat No. 46. Melbourne: Cancer Council Victoria, 2009.
2. English D, Farrugia H, Thursfield V, et al. Cancer survival Victoria 2007. Estimates of survival in 2004 (and comparisons with earlier periods). Melbourne: Cancer Council Victoria, 2007.
3. Nitecki SS, Sarr MG, Colby TV, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59-66.
4. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.
5. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the US: utilization, outcomes, and the effect of hospital volume. Cancer 2007; 110: 1227-1234.
6. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7.
7. Gunderson LL, Martin JK, Kvols LK, et al. Intra-operative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1987; 13: 319-329.
8. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80: 751-755.
9. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705-1710. (Pubitemid 11022870)
10. Verslype C, Van Cutsem E, Dicato M, et al. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol 2007; 18 Suppl 7: vii1-vii10.
11. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277.
12. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
13. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903. (Pubitemid 15040883)
14. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-782; discussion 782-784.
15. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299: 1019-1026.
16. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
17. Staples M, Elwood M, St John J, et al. Perceived impact on clinical practice and logistical issues in clinical management surveys of cancer: Australian experience. Qual Saf Health Care 2009; 18: 195-198.
18. Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol 2003; 21: 3409-3414.
19. Jefford M, Jennens R, Speer T, Thursfield V. Different professionals' knowledge and perceptions of the management of people with pancreatic cancer. Asia Pac J Clin Oncol 2007; 3: 44-51. (Pubitemid 46243281)
20. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-2001 FFCD/SFRO study. Ann Oncol 2008; 19: 1592-1599.
21. Loehrer PJ, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 [abstract]. J Clin Oncol 2008; 26 (15S): 4506.
22. Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg 2006; 244: 332-333; author reply 333.